PAHC

MKT CAP:$2B

Phibro Animal Health Corporation

Market Cap

$2B

Healthcare·Drug Manufacturers - Specialty & Generic·🇺🇸 United States·NASDAQ

Healthcare·Drug·🇺🇸·NASDAQ

Stock Price

$54.70+$17.40 (+46.65%)

Apr 24, 2026

Company Details

Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition...

CEO

Jack Clifford Bendheim

IPO Date

Apr 11, 2014

Website

www.pahc.com

Key Metrics TTM

Revenue

$1.5B

+32.4% YoY

Net Income

$92M

EPS (Diluted)

$2.25

Free Cash Flow

$47M

Revenue / Share

$35.75

Gross Margin

31.9%

Operating Margin

11.6%

Net Margin

6.3%

FCF Margin

3.2%

P/S

1.5x

P/E

24.3x

Earnings Reports

Q3 2026

May 6, 2026

PENDING

Q2 2026

Feb 4, 2026

$374M+20.9%EPS $0.67

Q1 2026

Nov 5, 2025

$364M+39.7%EPS $0.65

FY 2025

Aug 27, 2025

$1.3B+27.4%EPS $1.19

Q4 2025

Aug 27, 2025

$379M+38.6%EPS $0.42

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q3 22	$240M	$72M	$19M
Q4 22	$255M	$78M	$23M
Q1 23	$233M	$69M	$14M
Q2 23	$245M	$77M	$16M
Q3 23	$246M	$76M	$19M
Q4 23	$255M	$77M	$24M
Q1 24	$231M	$68M	-$726.0K
Q2 24	$250M	$79M	$16M
Q3 24	$263M	$80M	$20M
Q4 24	$273M	$87M	$18M
Q1 25	$260M	$83M	$18M
Q2 25	$309M	$102M	$26M
Q3 25	$348M	$105M	$34M
Q4 25	$379M	$110M	$34M
Q1 26	$364M	$120M	$48M
Q2 26	$374M	$133M	$54M

Valuation

Quarter	P/S	P/E
Q3 22	2.5x	38.0x
Q4 22	2.4x	45.5x
Q1 23	2.3x	48.1x
Q2 23	2.3x	61.7x
Q3 23	2.3x	78.2x
Q4 23	2.3x	68.6x
Q1 24	2.3x	107.9x
Q2 24	2.3x	151.2x
Q3 24	2.2x	170.0x
Q4 24	2.2x	925.9x
Q1 25	2.1x	128.5x
Q2 25	2.0x	115.8x
Q3 25	1.9x	70.4x
Q4 25	1.7x	46.3x
Q1 26	1.6x	33.0x
Q2 26	1.5x	24.3x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q3 22	$6M	-$4M
Q4 22	$2M	-$10M
Q1 23	-$11M	-$34M
Q2 23	-$2M	-$12M
Q3 23	$6M	-$2M
Q4 23	$20M	$9M
Q1 24	$16M	$9M
Q2 24	$32M	$21M
Q3 24	$11M	$2M
Q4 24	$28M	$15M
Q1 25	$13M	$3M
Q2 25	$3M	-$5M
Q3 25	$43M	$35M
Q4 25	$21M	$8M
Q1 26	$9M	-$5M
Q2 26	$19M	$8M

Capital Expenditures

Quarter	CapEx
Q3 22	$10M
Q4 22	$12M
Q1 23	$23M
Q2 23	$10M
Q3 23	$8M
Q4 23	$11M
Q1 24	$7M
Q2 24	$11M
Q3 24	$10M
Q4 24	$13M
Q1 25	$10M
Q2 25	$8M
Q3 25	$8M
Q4 25	$13M
Q1 26	$14M
Q2 26	$11M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 22	+13.2%	+15.0%
Q4 22	+15.9%	+15.5%
Q1 23	+8.3%	+9.4%
Q2 23	+5.1%	+8.7%
Q3 23	+2.5%	+3.0%
Q4 23	-0.1%	-0.5%
Q1 24	-0.5%	+6.0%
Q2 24	+2.2%	+2.4%
Q3 24	+7.1%	+7.1%
Q4 24	+7.1%	+10.1%
Q1 25	+12.6%	+4.6%
Q2 25	+23.7%	+21.1%
Q3 25	+32.1%	+29.2%
Q4 25	+38.6%	+35.4%
Q1 26	+39.7%	+30.2%
Q2 26	+20.9%	+12.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q3 22	$0	0.0%
Q4 22	$0	0.0%
Q1 23	$0	0.0%
Q2 23	$0	0.0%
Q3 23	$0	0.0%
Q4 23	$0	0.0%
Q1 24	$81.0K	0.0%
Q2 24	$80.0K	0.0%
Q3 24	$135.0K	0.1%
Q4 24	$179.0K	0.1%
Q1 25	$179.0K	0.1%
Q2 25	$180.0K	0.1%
Q3 25	$179.0K	0.1%
Q4 25	$179.0K	0.0%
Q1 26	$339.0K	0.1%
Q2 26	$434.0K	0.1%

OpEx Breakdown

Quarter	SG&A
Q3 22	$52M
Q4 22	$56M
Q1 23	$55M
Q2 23	$62M
Q3 23	$57M
Q4 23	$53M
Q1 24	$68M
Q2 24	$63M
Q3 24	$60M
Q4 24	$69M
Q1 25	$66M
Q2 25	$76M
Q3 25	$71M
Q4 25	$76M
Q1 26	$71M
Q2 26	$78M

Revenue Segments

Quarter	Animal Health	Mineral Nutrition	Performance Products
Q4 23	$177M	$58M	$20M

Revenue by Geography

Quarter	Asia Pacific	Europe, Middle East and Africa	Latin America and Canada	United States	Emea
Q3 22	$18M	$30M	$45M	$147M	—
Q1 23	$15M	—	$52M	$136M	$30M
Q2 23	$14M	—	$54M	$149M	$28M
Q3 23	$15M	—	$54M	$149M	$28M
Q4 23	$18M	—	$60M	$145M	$32M
Q1 24	$14M	—	$59M	$131M	$27M
Q2 24	$15M	—	$65M	$140M	$30M
Q3 24	$17M	—	$54M	$159M	$33M
Q4 24	$17M	—	$70M	$154M	$32M
Q1 25	$15M	—	$71M	$144M	$31M
Q2 25	$20M	—	$73M	$184M	$33M
Q3 25	$28M	—	$71M	$210M	$39M
Q4 25	$35M	—	$84M	$202M	$58M
Q1 26	$29M	—	$87M	$202M	$45M
Q2 26	$20M	—	$88M	$222M	$45M

War Chest

Quarter	Cash	Short-term Investments	Total
Q3 22	$71M	$22M	$93M
Q4 22	$74M	$17M	$91M
Q1 23	$76M	$10M	$86M
Q2 23	$68M	$10M	$78M
Q3 23	$37M	$40M	$77M
Q4 23	$41M	$40M	$81M
Q1 24	$43M	$48M	$91M
Q2 24	$33M	$60M	$92M
Q3 24	$50M	$49M	$99M
Q4 24	$71M	$44M	$115M
Q1 25	$52M	$38M	$90M
Q2 25	$67M	$0	$67M
Q3 25	$60M	$10M	$70M
Q4 25	$68M	$9M	$77M
Q1 26	$73M	$13M	$85M
Q2 26	$55M	$19M	$75M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q3 22	41M	0.0%	0.0%
Q4 22	41M	-0.0%	0.0%
Q1 23	41M	+0.0%	0.0%
Q2 23	41M	0.0%	0.0%
Q3 23	41M	-0.0%	-0.0%
Q4 23	41M	+0.0%	+0.0%
Q1 24	41M	-0.0%	-0.0%
Q2 24	41M	+0.0%	0.0%
Q3 24	41M	+0.0%	+0.0%
Q4 24	41M	+0.0%	+0.0%
Q1 25	41M	+0.1%	+0.2%
Q2 25	41M	+0.3%	+0.5%
Q3 25	41M	-0.0%	+0.5%
Q4 25	41M	-0.0%	+0.4%
Q1 26	41M	+0.4%	+0.7%
Q2 26	41M	+0.2%	+0.6%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q3 22	$138.9K	2K
Q4 22	$137.2K	2K
Q1 23	$125.0K	2K
Q2 23	$131.5K	2K
Q3 23	$132.1K	2K
Q4 23	$132.8K	2K
Q1 24	$120.5K	2K
Q2 24	$130.2K	2K
Q3 24	$137.1K	2K
Q4 24	$140.8K	2K
Q1 25	$134.2K	2K
Q2 25	$159.4K	2K
Q3 25	$179.3K	2K
Q4 25	$153.0K	2K
Q1 26	$147.0K	2K
Q2 26	$151.1K	2K

Revenue / Employee